PRA Health Sciences Inc. (NASDAQ:PRAH) previous close was $171.90 while the outstanding shares total 64.80M. The firm has a beta of 1.31, a 12-month trailing P/E ratio of 52.13, and a growth ratio of 3.43. PRAH’s shares traded lower over the last trading session, losing -0.93% on 05/18/21. The shares fell to a low of $169.87 before closing at $170.30. Intraday shares traded counted 1.03 million, which was -10.58% lower than its 30-day average trading volume of 932.34K. The stock’s Relative Strength Index (RSI) is 64.78, with weekly volatility at 1.08% and ATR at 2.23. The PRAH stock’s 52-week price range has touched low of $90.79 and a $173.24 high.
Investors have identified the Diagnostics & Research company PRA Health Sciences Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $11.01 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
PRA Health Sciences Inc. (PRAH) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For PRAH, the company has in raw cash 690.26 million on their books with 116.3 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 1.6 billion total, with 1.32 billion as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 5.91 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on PRAH sounds very interesting.
Is the stock of PRAH attractive?
In related news, EVP & CFO, Bonello Michael J. sold 2,048 shares of the company’s stock in a transaction that recorded on Apr 26. The sale was performed at an average price of 166.77, for a total value of 341,545. As the sale deal closes, the EVP, CAO & General Counsel, Gaenzle Christopher L now sold 3,136 shares of the company’s stock, valued at 407,805. Also, EVP & CFO, Bonello Michael J. sold 33,372 shares of the company’s stock in a deal that was recorded on Dec 17. The shares were price at an average price of 120.12 per share, with a total market value of 4,008,645. Following this completion of acquisition, the President & CEO, SHANNON COLIN now holds 6,073 shares of the company’s stock, valued at 624,790. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
1 out of 11 analysts covering the stock have rated it a Buy, while 10 have maintained a Hold recommendation on PRA Health Sciences Inc.. 0 analysts has assigned a Sell rating on the PRAH stock. The 12-month mean consensus price target for the company’s shares has been set at $170.00.